Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer

Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R. Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C. McDonald; Cynthia R. Cherry; Meghan Shea; Mark S. Huberman; Paul A. VanderLaan; Glen J. Weiss; Paul R. Walker; Daniel B. Costa; Deepa Rangachari

doi:10.1101/2020.03.31.20048637

Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer

View ORCID ProfileKartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Glen J. Weiss, Paul R. Walker, Daniel B. Costa, Deepa Rangachari

doi: https://doi.org/10.1101/2020.03.31.20048637

Kartik Sehgal

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

M.B.B.S.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Kartik Sehgal
For correspondence: ksehgal{at}bidmc.harvard.edu drangach{at}bidmc.harvard.edu

Anushi Bulumulle

bDivision of Hematology and Oncology, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA

cVidant Medical Center, Greenville, NC 27834, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Heather Brody

bDivision of Hematology and Oncology, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA

cVidant Medical Center, Greenville, NC 27834, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ritu R. Gill

dDepartment of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

MD, MPH

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shravanti Macherla

bDivision of Hematology and Oncology, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA

cVidant Medical Center, Greenville, NC 27834, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Aleksandra Qilleri

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Danielle C. McDonald

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

NP, MSN

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Cynthia R. Cherry

cVidant Medical Center, Greenville, NC 27834, USA

MSN-AGNP

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Meghan Shea

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark S. Huberman

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul A. VanderLaan

eDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

MD, PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Glen J. Weiss

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

MD, MBA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul R. Walker

bDivision of Hematology and Oncology, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA

MD, FACP

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniel B. Costa

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

MD, PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Deepa Rangachari

aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: ksehgal{at}bidmc.harvard.edu drangach{at}bidmc.harvard.edu

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Supplementary Table S1
Supplementary Table S2
Supplementary Table S3
Supplementary Table S4
Supplementary Figure S1

Supplementary Figure 1
Supplementary Table 1
Supplementary Table 2
Supplementary Table 3
Supplementary Table 4

View the discussion thread.

PreviousNext

Posted May 31, 2020.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer

Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Glen J. Weiss, Paul R. Walker, Daniel B. Costa, Deepa Rangachari

medRxiv 2020.03.31.20048637; doi: https://doi.org/10.1101/2020.03.31.20048637

Share This Article: